From: miRNA signature associated with outcome of gastric cancer patients following chemotherapy
 | Gastric cancer patient | Healthy volunteer | |
---|---|---|---|
 | Training set | Proof-of-principle test set (responder) |  |
Number | 82 | 8 | 34 |
Age - yr | Â | Â | Â |
   Median | 56 | 56 | 48 |
   Interquartile range | (44-63) | (44-58) | (43-57) |
Sex - no. (%) | Â | Â | Â |
   Male | 64 (78.0%) | 7 (87.5%) | 23 (67.6%) |
   Female | 18 (22.0%) | 1 (12.5%) | 11 (32.4%) |
Performance status (PS) - no. (%) | Â | Â | Â |
   ECOG1 PS 0 or 1 | 73 (89.0%) | 8 (100%) |  |
   ECOG PS 2 or 3 | 9 (11.0%) | 0 |  |
Histological type - no. (%) | Â | Â | Â |
   Lauren's intestinal | 34 (41.5%) | 3 (37.5%) |  |
   Lauren's diffuse | 48 (58.5%) | 5 (62.5%) |  |
Location of primary lesion - no. (%) | Â | Â | Â |
   Upper 1/3 | 11 (13.4%) | 1 (12.5%) |  |
   Middle 1/3 | 18 (22.0%) | 5 (62.5%) |  |
   Lower 1/3 | 43 (52.4%) | 1 (12.5%) |  |
   Entire stomach | 10 (12.2%) | 1 (12.5%) |  |
Chemotherapy regimen - no. (%) | Â | Â | Â |
   Cisplatin/Fluorouracil | 80 (97.6%) | 8 (100%) |  |
   Cisplatin/Capecitabine | 2 (2.4%) | 0 |  |
*Relative dose intensity - % | Â | Â | Â |
   Median | 81.2 | 76.6 |  |
   Interquartile range | (75.3-87.3) | (64.7-84.9) |  |
Number of chemotherapy cycles | Â | Â | Â |
   Median | 4 | 10 |  |
   Interquartile range | (2-5) | (7-11) |  |
Chemotherapy response (WHO criteria) -no (%) | Â | Â | Â |
   PR2 | 16 (24.6%) | 6 (100%) |  |
   SD3 | 25 (38.5%) |  |  |
   PD4 | 24 (36.9%) |  |  |
   Unmeasurable | 16 | 2 |  |
   Unevaluable | 1 |  |  |
Second-line chemotherapy | 55 (67.1%) | 6 (75.0%) | Â |
Median follow-up for survivors | 35.5 months | - | Â |
Overall survival - mo. | Â | Â | Â |
   Median | 8.2 | 16 |  |
   Interquartile range | (6.8-10.5) | (11.3-26.7) |  |
Time to progression - mo . | Â | Â | Â |
   Median | 3.1 | 8.2 |  |
   Interquartile range | (2.5-3.9) | (4.3-21.2) |  |